Kornimate/medical-research-clean huggingface dataset:
artificial intelligence in mental illness diagnosis and treatment

Conditions: Artificial Intelligence; Mental Illness

Summary: to improve the quality of mental health services, we will develop a robot that includes disease screening, diagnosis, treatment, and follow-up. the effectiveness of robots will be verified in a prospective, randomized, multi-center clinical trial. we assume that the robot will reduce the differences in the experience of doctors of different years and will improve mental health care across the country, and improve the uneven distribution of mental health resources through remote resource sharing.

anxiety disorder is the most common mental disorder in the world. the lifetime prevalence of anxiety disorder in china is as high as 7.6%, but the treatment rate is less than 30%, and the standard treatment rate is only 9.8%. the disease burden is heavy, and it is one of the most serious public health problems in china. anxiety disorder is a chronic relapsing disease, single drug treatment only 35-50% efficient, psychological treatment as the most international evidence-based foundation and anxiety disorder most commonly used treatment method, can be a single treatment for anxiety disorders or improve the effect of the medication, but because of clinical psychology in china started late, the lack of professionals, unable to meet the huge demand for psychological treatment in our country, therefore, how to develop efficient and standardized anxiety disorders psychotherapy pattern, improve the psychological treatment of acquired, is the key to improve the clinical curative effect of anxiety disorders. based on the intelligent assisted psychotherapy system based on cognitive behavior and mindfulness developed in the early stage, this research group established the accurate psychotherapy artificial intelligence robot based on evaluation to assist the whole process of standardized psychotherapy for anxiety disorders.

Eligibility criteria:
inclusion criteria: * community high-risk groups and institutional groups. * according to the icd-11 diagnostic guidelines of anxiety-related disorders, depression-related disorders, addiction-related disorders, compulsive-related disorders diagnosis, * age 18-60 years old, * skilled in the operation of computers or smartphones, * language, reading ability is normal, * willing to participate in the project and sign informed consent study. exclusion criteria: * the symptoms of mental illness are severe and require hospitalization, or the patient is unable to complete the required assessment examination and treatment. * those who have a higher risk of self-injury or suicide. * people with severe physical illness, central system disease, or substance abuse. * receive physical therapy at the same time.
evaluation of integrated optimization schemes for female stress incontinence

Conditions: Stress Urinary Incontinence in Women

Summary: the aim of this study is to determine the effectiveness of pfmt added to ea vs pfmt added sham ea for sui in women.

we will perform a multicenter, randomized, double-blind, sham-controlled, parallel-group clinical trial in four hospitals in china to compare the effectiveness of ea added to pfmt vs sham ea added to pfmt for women with sui. the participated women with sui will be recruited from four participating hospitals or through community clinics by advertising. participated hospitals include: yueyang hospital of integrated traditional chinese and western medicine affiliated to shanghai university of traditional chinese medicine (shanghai, china); shaanxi hospital of traditional chinese medicine (xi'an, china); first teaching hospital of tianjin university of traditional chinese medicine (tianjin, china); and nanjing hospital of chinese medicine affiliated to nanjing university of chinese medicine (nanjing, china). patients will be screened for eligibility. chief complaint, medical history, and general characteristics (such as age, race, education level, body mass index, manner of child delivery, menopause) will be obtained. those who met inclusion criteria and are interested in participating in the study will sign an informed consent form and then make another appointment to complete the baseline data collection, including the 72-hr bladder diary, 1-h pad test, international consultation on incontinence questionnaire-short form (iciq-sf) score, the weekly mean number of urine pads used). participants will then be assigned randomly to either a pfmt (3 sets/day for 8 weeks) + ea (3 times per week for 8 weeks) group or a pfmt + sham ea group. the primary and secondary outcome will be measured from week 2 to 32. the participant-reported severity of ui and subjective self-evaluation of therapeutic effects will be recorded. written informed consent will be obtained from all participants before they are included in the study. all clinical investigations will be conducted according to the principles of the declaration of helsinki.

Eligibility criteria:
inclusion criteria: * women who are 40-75 years of age * involuntary leakage of urine during increased intra-abdominal pressure in the absence of a bladder contraction, such as coughing, sneezing, or other physical activities * a 1-hour pad test exceeds 1 g * no other treatments are administered for urinary incontinence currently exclusion criteria: * subject has urgency and mixed urinary * subjects with pelvic organ prolapse, pregnancy, a history of pelvic surgery, chronic respiratory diseases, urinary tract infection, cardiac pacemaker installation, metal allergy, severe needle fear, and currently taking medications for sui or psychological disorders.

Keywords: stress urinary incontinence; acupuncture
evaluation of the impact of sports-inspired onco-coaching on health-related quality's life of the patients in cancer remission after allogeneic transplantation of hematopoietic stem cells

Conditions: Hematological Cancer

Summary: to measure the impact of a coaching program on the patient's health-related quality of life 15 months post-transplant (m15/r12).

after signing the consent form and validating the inclusion and non-inclusion criteria, patients will be included in the study. they will be randomized unequally (2:1) into one of the study groups: * oc (onco-coaching) group: patients will undergo onco-coaching sessions at a rate of 1 session/month until 6 months post-inclusion (m9/r6). 73 patients will be randomized in this group * group c (control): patients will not receive onco-coaching follow-up, but will be able to benefit from classical management in full autonomy. 35 patients will be randomized in this group

Eligibility criteria:
inclusion criteria: 1. be at least 18 years of age and have a good understanding and practice of the french language, 2. have been treated by an allogeneic hematopoietic stem cell transplant 3. signed consent to participate, 4. affiliation with a social security plan, or beneficiary of such a plan. exclusion criteria: 1. patients under treatment for complications (infections, gvhd,...) except patients with cgvhd requiring corticosteroid therapy less than or equal to 1 mg/kg daily 2. patient with progressive or relapsing hematological disease, 3. person in an emergency situation, adult under legal protection (guardianship, curatorship or safeguard of justice), or unable to express his/her consent, 4. person requiring psychotherapeutic care 5. impossibility to submit to the follow-up of the trial for geographical, social or psychological reasons.
medico-economic comparison of postpartum hemorrhage management using the bakri balloon and standard care

Conditions: Postpartum Hemorrhage

Summary: this study concerns women diagnosed with postpartum hemorrhage and requiring sulprostone therapy. included patients are randomized to two arms: the "sulprostone + bakri balloon" arm versus the "sulprostone alone" arm. the main objective of this study is to compare the efficiency of a care strategy including the bakri balloon to that of routine care without the bakri balloon via a cost-consequence study juxtaposing costs and the necessity of invasive procedures (arterial embolization, ligation of arteries, hysterectomy, intrauterine sutures) for controlling postpartum hemorrhage.


Eligibility criteria:
inclusion criteria: * the patient, her person-of-trust, must have given his/her consent and signed the consent form / inclusion decision made by the investigator when a person-of-trust is absent * the patient must be insured or beneficiary of a health insurance plan * the patient is able to fluently read and speak french * blood loss \> 500ml and sulprostone treatment is insufficient at 20 minutes * duration of pregnancy \> 32 weeks of amenorrhea * uterine atony exclusion criteria: * the patient is participating in another study except for the followin studies: elastomap, elastodéclench, papillo pma, grosspath, lxrs, dgpostpartum * the patient is in an exclusion period determined by a previous study * the patient is under judicial protection, under tutorship or curatorship * the patient refuses to sign the consent * it is impossible to correctly inform the patient * the patient cannot read french * the patient was transferred to another center not among the centers participating in this study * the patient has a contraindication for a treatment used in this study (sulprostone), or an incompatible treatment combination * the patient has a contraindication for third level techniques * the patient has at least one of the following conditions: chorioamnionitis, cervical cancer, uterine rupture, anatomical abnormality preventing the introduction of the device, purulent infection of the vagina, cervix or uterus.

Keywords: bakri balloon
contrast-enhanced ultrasonography in diagnosing early-stage ovarian cancer in patients with an adnexal mass undergoing surgery to remove the ovary

Conditions: Ovarian Cancer

Summary: rationale: new diagnostic procedures, such as contrast-enhanced ultrasonography, may be an effective method of finding ovarian cancer. purpose: this clinical trial is studying how well contrast-enhanced ultrasonography works in diagnosing early-stage ovarian cancer in patients with an adnexal mass undergoing surgery to remove the ovary.

objectives: * determine whether use of a contrast agent improves the images of the ovaries during ultrasonography. outline: this is a multicenter study. patients may undergo baseline transabdominal or transvaginal ultrasonography, if not already done. patients then undergo contrast-enhanced transabdominal or transvaginal ultrasonography using perflutren lipid microspheres (definity®) iv. pathology reports from tissue collected during subsequent oophorectomy is analyzed and compared with ultrasonography findings.

Eligibility criteria:
disease characteristics: * diagnosis of adnexal mass * scheduled to undergo surgical oophorectomy patient characteristics: * not pregnant or nursing * negative pregnancy test * no known respiratory failure as manifested by signs and symptoms of carbon dioxide retention or hypoxemia * no pulmonary vasculitis * no known history of severe emphysema * no known history of pulmonary emboli * no other condition that causes pulmonary hypertension due to compromised pulmonary arterial vasculature * no known history of severe pulmonary hypertension (i.e., systolic pulmonary artery pressures \> 90 mm hg) * no known history of congenital heart defect that creates a bidirectional or right-to-left shunt * no worsening or clinically unstable congestive heart failure * no known acute myocardial infarction or acute coronary syndromes * no known serious ventricular arrhythmias * not at high risk for arrhythmia due to prolongation of the qt interval * no known or suspected hypersensitivity to blood, blood products, or albumin * no known hypersensitivity to perflutren * no known or suspected hypersensitivity to octafluoropropane or any other ingredients of perflutren lipid microspheres (definity®) * no mental status problems, illiteracy, or other circumstance that would preclude giving informed consent prior concurrent therapy: * see disease characteristics

Keywords: ovarian germ cell tumor ovarian epithelial cancer
a study combining personalized neoantigen-based dendritic cell vaccine with microwave ablation for the treatment of hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma; Liver Cancer, Adult

Summary: this is a single institution, open-label, multi-arm, pilot study of a personalized neoantigen-based dendritic cell (dc) vaccine combined with microwave ablation in subjects with hepatocellular carcinoma (hcc). patients with hklc stage iia hcc are eligible for enrollment. in this study, the investigators are looking at the safety, feasibility of the personalized neoantigen-based dc vaccine combined with microwave ablation as well as the t cell immune response to the vaccine.


Eligibility criteria:
inclusion criteria: 1. histologically confirmed patients with primary hepatocellular carcinoma, hklc stage iia. 2. age is greater than 18 years old, male or female. 3. the tumor size is 3cm-5cm, and the lesions are \<3. 4. ecog score \< 2, child-pugh classification a or b. 5. the participants freely sign informed consent; exclusion criteria: 1. pregnant or breast-feeding; psychiatric problems, addiction, or any other disorder that prevented informed consent; 2. portal vein thrombosis or extrahepatic metastases; 3. white blood cell count \ 110 mol/l, aspartate aminotransferase \>3 times upper limit, serum bilirubin \> 2.5 times upper limit, prothrombin time\> 19 seconds. 4. active uncontrolled infection; 5. concurrent systemic corticosteroid treatment 6. primary immunodeficiency or systemic autoimmune disease; being treated with immunosuppressive drugs for other diseases; 7. clinically significant ischemic heart disease or cardiac failure; 8. the investigator believes that there are other reasons that are not suitable for inclusion.

Keywords: neoantigen vaccine dendritic cell personalized liver cancer
pd-1 inhibitor, azacitidine and low-dose dli in aml relapse after allo-hsct

Conditions: Acute Myeloid Leukemia

Summary: this study aims to evaluate the efficacy and safety of pd-1 inhibitor, azacitidine, and low-dose dli in aml relapse after allogeneic hematopoietic stem cell transplantation


Eligibility criteria:
inclusion criteria: 1. patients with a diagnosis of aml relapse after allogeneic hematopoietic stem cell transplantation. 2. adequate organ function. 3. be able to understand and sign informed consent. 4. age 18 to 60 years old. 5. serum pregnancy test for females of childbearing potential that is negative within one week prior to initiation of first dose of treatment. female patients of childbearing potential and sexually active males must agree to use a highly effective method of contraception throughout the study and for at least 90 days after the last dose of assigned treatment. 6. ecog performance status ≤ 1. 7. known hla-matched donor without contraindications to donate. 8. life expectancy \> 3 months. exclusion criteria: 1. diagnosis of anther malignant disease. 2. suspected or proven acute or chronic gvhd. 3. proven central nervous system leukemia. 4. prior treatment with anti-pd-1, anti-pd-l1, or dli. 5. hla loss positive. 6. known active viral infection with known human immunodeficiency virus (hiv) or viral hepatitis type b (hbv) or c (hcv) or corona virus disease 2019(covid-19); 7. uncontrolled systemic fungal, bacterial, or viral infection. 8. known or suspected hypersensitivity to pd-1 inhibitor or azacytidine. 9. participation in another clinical study within 3 months. 10. any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of study procedures.

Keywords: pd-1 inhibitor azacitidine low-dose dli
secretory otitis media in adenoids hypertrophy patients

Conditions: Otitis Media With Effusion

Summary: this study aims to compare the fate of secretory otitis media in patients with adenoids hypertrophy undergoing adenoidectomy alone or with myringotomy or with myringotomy and tympanostomy tube application

otitis media with effusion (ome) is one of the most common diseases during childhood . it is defined as collection of non-purulent effusion (mucoid or serous) in the middle ear space without signs of acute infection. it's synomus are serous otitis media, secretory otitis media or glue ear. adenoid hypertrophy can cause mechanical obstruction of the eustachian tube which plays an important role in the pathogenesis of ome. management of ome consisted of many varieties; 1- auto inflation, 2- medical treatment and 3- surgical. surgical treatment indicated in cases where the effusion does not resolve spontaneously or failed medical treatment for 3 months and the main purpose of surgery is to restore middle ear aeration. treatment options are adenoidectomy with or without myringotomy or myringotomy and tympanostomy tube application. the aim of this study is to compare the efficacy of each surgical option in management of otitis media with effusion. this study will be carried out in ent department of assiut university hospital on 150 child diagnosed as persistent otitis media with effusion due to adenoid enlargement and they will be categorized randomly into three groups (50 cases per each). group i will undergo adenoidectomy alone, group ii will undergo adenoidectomy and myringotomy and group iii will undergo adenoidectomy and myringotomy and tympanostomy tube application. all patients will be subjected to full ent examination and audiological evaluation. postoperative evaluation will be done for all patients for 3 months through clinical and audiological evaluation.

Eligibility criteria:
inclusion criteria: * any case presented with secretory otitis media with adenoids hypertrophy with the following criteria * age is between 3 to 17 years old * with or without chronic tonsillitis * conductive hearing loss * recurrent upper respiratory tract infection * dull tympanic membrane on otoscopy (absent cone of light), decreased mobility of tympanic membrane * type b tympanogram on tympanometry * ome not responding to medical treatment for three months exclusion criteria: * patients with the following criteria will be excluded from the study * previous myringotomy with or without tympanostomy tube application * previous adenoidectomy or tonsillectomy * previous ear surgery, cleft palate, down's syndrome, congenital malformation of the ear and cholesteatoma.
elucidating the mechanism of remission of type 2 diabetes in morbid obese patients after bariatric surgery

Conditions: Morbid Obesity; Type2 Diabetes

Summary: the main aim of this study is to elucidate the mechanism of the remission of type 2 diabetes in the morbid obese patients after laparoscopic sleeve gastrectomy.

in this study four groups including: group i - morbid obese diabetics, group ii - morbid obese non diabetics, group iii - lean diabetics, and group iv - lean non diabetics will be studies. the bariatric surgical procedure should include laparoscopic sleeve gastrectomy (lsg). all participants will be assessed by members of a multidisciplinary obesity team including a surgeon, endocrinologist, dietician, and nurse specialist who will usually have input into patient selection. briefly the study will be explained to the each participant, and after his/her agreement, the informed consent form will be deliver to him/her for completion and signature. within a week before surgery each enrolled participant of group i and ii will be subjected to a medical questionnaire and other routine laboratory analyses before surgery such as fasting glucose, liver, renal, lipid and coagulation profiles. at this time a mixed meal tolerance test (mmtt) will be performed and blood samples will be collected for further analysis as it is described in the protocol. participants in group i and ii will be admitted at dasman diabetes institute for post-surgery follow up, performing mmtt, and donating blood samples on days 07, 15, 30, 60, 90, 180, and 360 post-surgery. adipose, muscle biopsies, and a sample from remnant surgical tissue from these participants will be harvested during of the lsg (days 0). participants in group i will be asked to monitor their fasting blood glucose level everyday at early morning and the dose of anti-hyperglycemia medications will be adjusted by the recommendation provided by the physician member of team. this data will be recorded as their continuous blood glucose monitoring. group iii and iv participants, as control groups with no surgical intervention, will be subjected to the medical questionnaire and other routine laboratory analyses and mmtt in just one visit. all demographic and clinical information collected from the participants will be recorded in the information form identified by identification number (id number). only samples from the cases that do not have any post-surgery related complications or not have any emergency clinical condition will be used for genomics and proteomics analysis.

Eligibility criteria:
inclusion criteria: * adults * type 2 diabetes \<5 years * male and female, * resident of kuwait, * who agreed to participate in the study exclusion criteria: * pregnancy, * malignancy, * type 1 diabetes, * type 2 diabetes with more than 5 years, * and history with overt heart and/or kidney failure
whole body magnetic resonance angiography in ischemic patients at 1.5 and 3t

Conditions: Atherosclerosis; Intermittent Claudication; MRI

Summary: to investigate the diagnostic performance of whole body magnetic resonance angiography (wb-mra) using two different magnetic resonance scanners at a field strength of 1.5 and 3t. the hypothesis is that use of the 3t system gives superior signals from the investigated arteries, when compared with 1.5t.

atherosclerosis of the lower leg arteries is a common disease. patients with this condition has symptoms of ischemia, for instance intermittent claudication (pain during exercise). diagnosis of atherosclerosis in the legs is normally done with an interventional x-ray-based angiography (dsa- digital subtraction angiography). this is uncomfortable for the patient, and associated with risks of complications (bleeding, vascular damage, embolism).a novel approach to diagnosing atherosclerosis is the use of magnetic resonance angiography. a variant of this is the whole body magnetic resonance angiography(wb-mra), that produce a picture of the arteries in almost the whole body (excluding the coronary arteries). wb-mra has a number of advantages compared to dsa. it does not use ionizing radiation, is not invasive, uses a contrast medium with fewer side affects and finally gives a covers a great deal of the arteries in the body. this study will compare wb-mra with dsa in patients with symptoms of peripheral atherosclerosis in the lower legs. all the patients will undergo arterial first pass whole-body mra in the 3t-system. this will be followed by a wb-mra steady state examination which can be performed because we use the intravascular contrast medium vasovist, that has a prolonged intravascular life. the steady state examination will be performed in both the 3t and the 1.5t mr-system. half the patients will have the steady state examination performed first in the 3t and then the 1.5t-system. the other half will go to the 1.5t-system first and then return to the 3t-system.

Eligibility criteria:
inclusion criteria: * symptomatic lower extremity ischemia (claudication, ischemic wounds) referred to digital subtraction angiography (dsa) exclusion criteria: * renal insufficiency (gfr \< 30 ml/min) * contra-indications for mri-examination (claustrophobia, metal-implants, pacemaker) * dementia * pregnancy/lactation * allergy to gadolinium based mri contrast agents * acute disease

Keywords: magnetic resonance whole body angiography vasovist gadofosveset blood pool agent 3t 1.5t field strength